Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series

Abstract Background The Coronavirus disease 2019 (COVID-19) caused by the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a pandemic, affecting the therapeutic management for Multiple Sclerosis (MS). Any decision regarding the discontinuation of high-potency agents for mo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Clara G. Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Arturo Montineri, Francesco Patti
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Multiple sclerosis COVID-19 SARS-CoV-2 active infection Natalizumab Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/0bf582194b9040e3bc74df823d15f075
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0bf582194b9040e3bc74df823d15f075
record_format	dspace
spelling	oai:doaj.org-article:0bf582194b9040e3bc74df823d15f0752021-12-05T12:08:52ZNatalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series10.1186/s12883-021-02421-31471-2377https://doaj.org/article/0bf582194b9040e3bc74df823d15f0752021-11-01T00:00:00Zhttps://doi.org/10.1186/s12883-021-02421-3https://doaj.org/toc/1471-2377Abstract Background The Coronavirus disease 2019 (COVID-19) caused by the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a pandemic, affecting the therapeutic management for Multiple Sclerosis (MS). Any decision regarding the discontinuation of high-potency agents for moderate and highly active MS should be carefully evaluated, taking into account the potential risk of rebound of the disease. In particular, no data about clinical outcome of patients with MS receiving Natalizumab (NTZ) during active COVID-19 infection have been reported yet. Cases presentation We reported on 6 patients treated with NTZ for relapsing MS during active COVID-19 infection, who recovered without reporting any worsening or new symptoms. Most of the patients were asymptomatic, with the exception of one patient who had a slight worst COVID-19 clinical course. No patients received O2-therapy or required intensive care. No neurological complications were observed. Conclusions This paper reported the clinical outcome of patients with MS receiving NTZ during active COVID-19 infection. This case series suggests that treatment with NTZ during pandemic is relatively safe and might be continued in selected patients who are infected by COVID-19, thereby reducing the risk of MS disease rebound.Clara G. ChisariSimona ToscanoSebastiano ArenaChiara FinocchiaroArturo MontineriFrancesco PattiBMCarticleMultiple sclerosisCOVID-19SARS-CoV-2 active infectionNatalizumabNeurology. Diseases of the nervous systemRC346-429ENBMC Neurology, Vol 21, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Multiple sclerosis COVID-19 SARS-CoV-2 active infection Natalizumab Neurology. Diseases of the nervous system RC346-429
spellingShingle	Multiple sclerosis COVID-19 SARS-CoV-2 active infection Natalizumab Neurology. Diseases of the nervous system RC346-429 Clara G. Chisari Simona Toscano Sebastiano Arena Chiara Finocchiaro Arturo Montineri Francesco Patti Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
description	Abstract Background The Coronavirus disease 2019 (COVID-19) caused by the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has become a pandemic, affecting the therapeutic management for Multiple Sclerosis (MS). Any decision regarding the discontinuation of high-potency agents for moderate and highly active MS should be carefully evaluated, taking into account the potential risk of rebound of the disease. In particular, no data about clinical outcome of patients with MS receiving Natalizumab (NTZ) during active COVID-19 infection have been reported yet. Cases presentation We reported on 6 patients treated with NTZ for relapsing MS during active COVID-19 infection, who recovered without reporting any worsening or new symptoms. Most of the patients were asymptomatic, with the exception of one patient who had a slight worst COVID-19 clinical course. No patients received O2-therapy or required intensive care. No neurological complications were observed. Conclusions This paper reported the clinical outcome of patients with MS receiving NTZ during active COVID-19 infection. This case series suggests that treatment with NTZ during pandemic is relatively safe and might be continued in selected patients who are infected by COVID-19, thereby reducing the risk of MS disease rebound.
format	article
author	Clara G. Chisari Simona Toscano Sebastiano Arena Chiara Finocchiaro Arturo Montineri Francesco Patti
author_facet	Clara G. Chisari Simona Toscano Sebastiano Arena Chiara Finocchiaro Arturo Montineri Francesco Patti
author_sort	Clara G. Chisari
title	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
title_short	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
title_full	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
title_fullStr	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
title_full_unstemmed	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
title_sort	natalizumab administration in multiple sclerosis patients during active sars-cov-2 infection: a case series
publisher	BMC
publishDate	2021
url	https://doaj.org/article/0bf582194b9040e3bc74df823d15f075
work_keys_str_mv	AT claragchisari natalizumabadministrationinmultiplesclerosispatientsduringactivesarscov2infectionacaseseries AT simonatoscano natalizumabadministrationinmultiplesclerosispatientsduringactivesarscov2infectionacaseseries AT sebastianoarena natalizumabadministrationinmultiplesclerosispatientsduringactivesarscov2infectionacaseseries AT chiarafinocchiaro natalizumabadministrationinmultiplesclerosispatientsduringactivesarscov2infectionacaseseries AT arturomontineri natalizumabadministrationinmultiplesclerosispatientsduringactivesarscov2infectionacaseseries AT francescopatti natalizumabadministrationinmultiplesclerosispatientsduringactivesarscov2infectionacaseseries
_version_	1718372173696991232

Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series

Ejemplares similares